首页> 美国卫生研究院文献>Experimental and Therapeutic Medicine >Effect of α-receptor blockers on lower urinary tract symptoms sexual function and quality of life in young and middle-aged men with benign prostatic hyperplasia
【2h】

Effect of α-receptor blockers on lower urinary tract symptoms sexual function and quality of life in young and middle-aged men with benign prostatic hyperplasia

机译:α受体阻滞剂对前列腺增生的中青年男性下尿路症状性功能和生活质量的影响

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The purpose of the present study was to compare the effectiveness of two common α1-receptor blockers, alfuzosin and tamsulosin, on lower urinary tract symptoms, sexual function, and quality of life in young and middle-aged people with benign prostatic hyperplasia. We recruited 80 young and middle-aged patients with benign prostatic hyperplasia and divided them into two groups that received either the non-selective α1-receptor blocker alfuzosin or the selective α1A-receptor blocker tamsulosin for 18 consecutive days. After intervention, maximum urinary flow, bladder compliance, maximum detrusor pressure, maximum urethral pressure, 72 h urination frequency and urination frequency at night, average urinary volume, residual urinary volume, urinary symptom distress score were significantly better in the tamsulosin group than in the alfuzosin group. Also, sperm density, sperm motility, sperm activity, and sperm DNA fragmentation index were significantly better in the tamsulosin group compared to the alfuzosin group. Finally, international index of erectile function-5 scores, increased libido and erection, retrograde ejaculation, and the quality of life were significantly better in the tamsulosin group compared to the alfuzosin group. Overall, tamsulosin effectively relieved the lower urinary tract symptoms, improved semen quality, and increased sexual life and quality of life in young and middle-aged patients with benign prostatic hyperplasia.
机译:本研究的目的是比较两种常见的α1受体阻滞剂阿夫唑嗪和坦索罗辛对前列腺增生的中青年人下尿路症状,性功能和生活质量的有效性。我们招募了80例前列腺增生的中青年患者,并将其分为连续18天接受非选择性α1受体阻滞剂阿夫唑嗪或选择性α1A受体阻滞剂坦索罗辛的两组。干预后,坦索罗辛组的最大尿流,膀胱顺应性,最大逼尿肌压力,最大尿道压力,72 h排尿次数和夜间排尿次数,平均尿量,残余尿量,尿液症状困扰评分明显优于坦索罗辛组。阿夫唑嗪组。此外,坦索罗辛组的精子密度,精子活力,精子活性和精子DNA碎片指数明显高于阿夫唑嗪组。最后,坦索罗辛组的国际勃起功能指数5分,性欲和勃起增加,逆行射精和生活质量明显优于阿夫唑嗪组。总体而言,坦索罗辛可有效缓解前列腺增生的年轻和中年患者的下尿路症状,改善精液质量并增加性生活和生活质量。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号